Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • DRUGS AND BIOLOGICS—U.S.: Three states file Supreme Court challenge against Democratic states’ shield laws
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—OTHER AGENCY DOCUMENTS: Market forces shape Medicare spending beyond payment rules
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • CONTROLLED SUBSTANCES—E.D. Tenn.: McKesson brought about the proper removal of an opioid diversion case to federal court
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • CONTROLLED SUBSTANCES—GAO REPORTS: GAO recommends DEA and FDA update policies on drug scheduling processes
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ENFORCEMENT ACTIONS—NOTICES: DEA revokes registration over federal health program exclusion
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • GENERAL HEALTH CARE NEWS—M.D. La.: Claim against MSA administrator for underpayment of medical bills dismissed
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • HEALTH CARE EMPLOYMENT ISSUES—7th Cir.: Hospital pharmacist’s vaccine-bias suit fails over accommodation hardship
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ORGAN PROCUREMENT AND TRANSPLANTATION—NOTICES: HRSA finalizes donor-focused organ donation reimbursement rules
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • SAFETY AND EFFECTIVENESS—NOTICES: FDA withdraws MYSOLINE suspension approval after manufacturer waives hearing rights
      • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, SAFETY AND EFFECTIVENESS—NOTICES: FDA withdraws MYSOLINE suspension approval after manufacturer waives hearing rights, (Oct 1, 2026)

    By WK Editorial Staff

    FDA’s withdrawal of approval for the MYSOLINE suspension application followed the manufacturer’s decision not to pursue reformulation or contest the agency’s action after longstanding contamination-related concerns prevented the ...

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use